A real-world study presented at finds zuranolone's PPD symptom improvements were sustained through day 90.
|Videos|November 8, 2021
Steven R. Goldstein, MD: Evaluating the uterus in women with perimenopausal or postmenopausal bleeding
Author(s)Lindsey Carr, Editor
In this interview, Steven R. Goldstein, MD, shares updated research on evaluating the uterus in women with perimenopausal and postmenopausal bleeding.
Advertisement
Advertisement
Related to this article
Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.
Maternal RSV immunization creates an important opportunity for obstetric and pediatric clinicians to coordinate newborn prevention strategies, according to Kevin Ault, MD.
A new Gallup survey found 51% of women in the United States reported negative healthcare experiences.
Hugh Taylor, MD, explains that imaging in endometriosis is best for ruling out other causes of pelvic pain and cannot exclude the diagnosis.
A new study links earlier menopause age to faster cognitive decline and earlier Alzheimer diagnosis.
The FDA office of Women's Health and Center for Drug Evaluation and Research and hosting a public workshop with a focus on testosterone use in menopausal women.
Bruce Dorr, MD, FACOG, URPS, FMCP-M, weighs his own experience with pellet therapy against guideline evidence, then he and Maria Uloko, MD, close with candid advice for clinicians too afraid of hormones to start prescribing.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
FDA holding public meeting on testosterone use in menopausal women
2
Survey: 51% of US-women report negative healthcare experiences
3
Contemporary OB/GYN Weekly Review: Testosterone evidence, ECV counseling, and more
4
Zuranolone shows sustained PPD symptom improvement through day 90
5